<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03204799</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0950</org_study_id>
    <nct_id>NCT03204799</nct_id>
  </id_info>
  <brief_title>Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes</brief_title>
  <official_title>Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Microbiota is important for immunology, hormonal and metabolic homeostasis in human and could
      influence on developing diabetes and obesity. Recent studies investigates microbiota by
      metagenomic sequencing, however, the composite of microbiota and its metabolic role has not
      been fully determined. Metagenomics and microbiome analysis could early diagnose metabolic
      disorders and suggest treatment options for metabolic diseases.

      In this study, the investigators investigate the composite of microbiota and deduct basic
      information for treatment models using metagenomic sequencing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Cross-section study: normal/prediabetes/drug naïve type2 diabetes: compare microbiota
           using metagenomic sequencing among three groups.

        2. Observational prospective study: metformin/sodium glucose co-transporter 2 (SGLT2)
           inhibitor/ezetimibe: compare microbiota using metagenomic sequencing before and after
           drug treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2016</start_date>
  <completion_date type="Anticipated">December 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metagenomic profile change</measure>
    <time_frame>10 days (acute effect)</time_frame>
    <description>Stool metagenomic profile change in acute and chronic phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metagenomic profile change</measure>
    <time_frame>3 months (chronic effect)</time_frame>
    <description>Stool metagenomic profile change in acute and chronic phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood glucose change</measure>
    <time_frame>3 months</time_frame>
    <description>fasting blood glucose</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>normal group</arm_group_label>
    <description>normal group (without diabetes diagnosis/treatment and in normoglycemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prediabetes</arm_group_label>
    <description>high risk, impaired fasting glucose, impaired glucose tolerance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug naive type 2 diabetes</arm_group_label>
    <description>type 2 diabetes, anti-hypoglycemic drug naive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>type 2 diabetes with metformin monotherapy</arm_group_label>
    <description>type 2 diabetes with metformin monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>type 2 diabetes with SGLT2 inhibitor monotherapy</arm_group_label>
    <description>type 2 diabetes with SGLT2 inhibitor monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dyslipidemia with ezetimibe therapy</arm_group_label>
    <description>dyslipidemia with ezetimibe therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>newly diagnosed type 2 diabetes patients who start to metformin monotherapy</description>
    <arm_group_label>normal group</arm_group_label>
    <arm_group_label>prediabetes</arm_group_label>
    <arm_group_label>drug naive type 2 diabetes</arm_group_label>
    <arm_group_label>type 2 diabetes with metformin monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2 inhibitor</intervention_name>
    <description>newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy</description>
    <arm_group_label>type 2 diabetes with SGLT2 inhibitor monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>newly diagnosed dyslipidemia patients who start to ezetimibe therapy</description>
    <arm_group_label>normal group</arm_group_label>
    <arm_group_label>prediabetes</arm_group_label>
    <arm_group_label>drug naive type 2 diabetes</arm_group_label>
    <arm_group_label>dyslipidemia with ezetimibe therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        type 2 diabetes patients with oral hypoglycemic agent/insulin naive
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal group: body mass index [BMI]&lt;23kg/m2, without diabetes mellitus history

          -  prediabetes group: fasting blood glucose ≥100 mg/dL and &lt;126 mg/dL or postprandial
             blood glucose ≥140 mg/dL and &lt;200 mg/dL

          -  type 2 diabetes according to ADA(American Diabetes Association) guideline (1) fasting
             blood glucose ≥126 mg/dL, (2) random blood glucose ≥200 mg/dL and with typical
             diabetes symptoms, (3) glycated hemoglobin A1c ≥6.5% and anti-hypoglycemic drug naive

          -  patients with type 2 diabetes, metformin monotherapy, SGLT2 inhibitor monotherapy

          -  patients with dyslipidemia, ezetimibe therapy

        Exclusion Criteria:

          -  inflammatory bowel disease (Crohn's disease, ulcerative colitis)

          -  history of stomach, small intestine or colon resection operation

          -  on antibiotics therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong-ho Lee, M.D., Ph.D.</last_name>
    <phone>82-2-2228-1943</phone>
    <email>yholee@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-ho Lee, M.D., Ph.D.</last_name>
      <phone>82-2-2228-1943</phone>
      <email>yholee@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

